1. P266 Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. (23rd April 2022) Authors: Coates, Laura C; Ogdie, Alexis; Gladman, Dafna D; Pournara, Effie; Meng, Xiangyi; Parikh, Bhumik; Mease, Philip J Journal: Rheumatology Issue: Volume 61(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. (March 2022) Authors: Strand, Vibeke; Kaeley, Gurjit S; Bergman, Martin J; Gladman, Dafna D; Coates, Laura C; Sherif, Bintu; Hur, Peter; Parikh, Bhumik; Gilloteau, Isabelle; Mease, Philip J Journal: Lancet Issue: Volume 4:Number 3(2022) Page Start: e208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗